Reporting Overseas Adverse Events of Medical Devices to HSA

1. Key takeaways

In principle, no. HSA states that adverse events occurring outside Singapore, where the devices have also been supplied in Singapore, generally do not require reporting to HSA; reporting is required only in two situations — where the registration or licence conditions of the device require it, or where a notice requesting adverse event information has been issued by HSA. Note the boundary: this exemption applies only to events that occur outside Singapore. It does not exempt any event that occurs within Singapore.

• The rule is territorial: it turns on where the event occurred, not on whether the product is sold in Singapore.
• Events occurring inside Singapore remain subject to the 48-hour / 10-calendar-day / 30-calendar-day tiers.
• The two exceptions — registration or licence conditions, and HSA-issued notices — must be checked case by case.
• Even exempt events may still trigger obligations to other regulators and internal quality system duties.

2. Legal basis

The exemption rests on the official HSA page on adverse event reporting of medical devices, issued under the Health Products Act 2007, Part VIII. The controlling language is worth reading in full.

3. Expert insights

Five observations on how this territorial rule plays out in practice.

Insight 1: this is a territorial rule, not a personal rule. HSA’s jurisdictional logic is anchored on the place where the event occurred, not on whether the product is sold in Singapore. Many companies instinctively reason from their commercial footprint — if the device is registered and sold in Singapore, every incident anywhere feels reportable — but that is not how the rule is written. The first question in every assessment is therefore always the same: where did the event occur? Events inside Singapore fall under the three-tier timelines without exception; events outside Singapore fall under the exemption, subject to the two exceptions below. Anchoring the analysis on the location of the event keeps the assessment objective and repeatable.

Insight 2: the two exceptions must be checked case by case; never assume they do not apply. First, registration or licence conditions: HSA may attach conditions when approving a registration or issuing a licence, and those conditions may include a duty to report overseas events. Archive the approval documents received at submission and verify the conditions line by line. Second, notices issued by HSA: HSA may issue a notice requesting adverse event information for particular products or matters. Once such a notice is received, the exemption no longer applies.

Insight 3: the exemption does not mean the event can be ignored. Even where an overseas event need not be reported to HSA, the manufacturer may still face other obligations: reporting duties to the regulator of the country where the event occurred; internal quality system requirements within the group, such as CAPA and trend analysis; and downstream effects on future Singapore filings — overseas events and FSCA history must be proactively disclosed in Annex 4, Part 2 of GN-15. A compliance team that treats the exemption as the end of the analysis leaves these duties unmanaged.

Insight 4: an overseas event that triggers an FSCA has knock-on effects in Singapore. If an overseas event leads to a global recall (FSCA), the recall action in Singapore must be notified to HSA under the Singapore rules (see Article 43), the FSCA history must be disclosed in new registration applications, and it may affect eligibility for the Immediate and Abridged routes — having no unclosed FSCA is one of the conditions. In other words, a single overseas incident can quietly reshape your regulatory strategy in Singapore months later, which is why the exemption should never be read as full disengagement.

Insight 5: the pre-disposition to report still applies. HSA’s overall posture on vigilance is that there should be a pre-disposition to report rather than not to report in case of doubt. When in doubt, lean towards reporting — this principle is especially useful when judging grey areas involving overseas events, where the territorial boundary itself may be unclear and the cost of an unnecessary report is far lower than the cost of a missed one.

4. Practical recommendations

We recommend the following workflow for assessing overseas adverse events affecting devices supplied in Singapore.

1. Determine the place where the event occurred first, then assess whether the exemption applies.
2. Verify the two exceptions case by case: registration or licence conditions in the approval documents, and whether any HSA notice has been received.
3. Route overseas events through the internal CAPA process anyway, and assess their impact on Singapore filings.
4. For overseas FSCAs, immediately assess the knock-on Singapore obligations, including recall notification and disclosure.
5. Lean towards reporting when in doubt: apply this principle to every grey-zone judgement.

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (official HSA adverse event reporting page; GN-15 Annex 4)

5. Verification checklist

• □ The place where the event occurred (domestic / overseas) has been confirmed
• □ Registration or licence conditions have been checked for overseas reporting requirements
• □ Whether a HSA notice requesting adverse event information has been received has been confirmed
• □ Overseas events are included in internal CAPA and trend analysis
• □ Knock-on Singapore obligations and disclosure requirements have been assessed for overseas FSCAs
• □ Grey-zone cases are handled under the lean-towards-reporting principle

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com